Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Expenses (2016 - 2025)

Celldex Therapeutics has reported Accumulated Expenses over the past 16 years, most recently at $47.0 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $47.0 million for Q4 2025, up 38.97% from a year ago — trailing twelve months through Dec 2025 was $47.0 million (up 38.97% YoY), and the annual figure for FY2025 was $47.0 million, up 38.97%.
  • Accumulated Expenses for Q4 2025 was $47.0 million at Celldex Therapeutics, up from $39.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CLDX hit a ceiling of $47.0 million in Q4 2025 and a floor of $7.0 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $12.5 million (2022), compared with a mean of $18.3 million.
  • Biggest five-year swings in Accumulated Expenses: decreased 27.17% in 2023 and later skyrocketed 262.02% in 2024.
  • Celldex Therapeutics' Accumulated Expenses stood at $8.0 million in 2021, then soared by 61.08% to $12.8 million in 2022, then decreased by 27.17% to $9.3 million in 2023, then skyrocketed by 262.02% to $33.8 million in 2024, then soared by 38.97% to $47.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $47.0 million (Q4 2025), $39.7 million (Q3 2025), and $28.4 million (Q2 2025) per Business Quant data.